News

Poor accrual halts one in five cancer clinical trials


 

AT THE GENITOURINARY CANCERS SYMPOSIUM

Trials were more likely to fail completion if they were funded by industry as compared with the federal government (hazard ratio, 1.97), were phase II as compared with phase III (HR, 1.29), or were single center as compared with multicenter (HR, 1.93).

On the other hand, trials were less likely to fail completion if they were conducted solely outside the United States (HR, 0.65) or both in and outside the United States (HR, 0.67), as compared with solely in the United States.

Dr. Galsky disclosed no relevant conflicts of interest.

Pages

Recommended Reading

Kidney cancer before age 47 implies hereditary cause
MDedge Hematology and Oncology
Statins may reduce prostate cancer deaths
MDedge Hematology and Oncology
Chronic use of NSAIDs, statins had no effect on PSA values
MDedge Hematology and Oncology
Focus chemoprevention on highest risk prostate cancer, expert says
MDedge Hematology and Oncology
Possible target in prostate cancer prevention research: 5-alpha reductase
MDedge Hematology and Oncology
Enzalutamide improves survival in chemo-naive metastatic prostate cancer
MDedge Hematology and Oncology
Radiation therapy has long-term benefit in prostate cancer
MDedge Hematology and Oncology
Metastatic RCC patients taking common antihypertensives lived longer
MDedge Hematology and Oncology
Test may help identify prostate cancer patients for active surveillance
MDedge Hematology and Oncology
Smokers at increased risk after prostate cancer radiation therapy
MDedge Hematology and Oncology